Related Experiment Video

Updated: Jun 17, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Potential of ErbB4 antibodies for cancer therapy

Maija Hollmén1, Klaus Elenius

  • 1Department of Medical Biochemistry and Genetics, and Medicity Research Laboratory, University of Turku, and Turku Graduate School of Biomedical Sciences, Turku, Finland.

Future Oncology (London, England)
|December 22, 2009
PubMed

Insights

Antibodies targeting ErbB4 receptors show promise for cancer therapy. This review explores ErbB4

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Monoclonal antibodies targeting Epidermal Growth Factor Receptor (EGFR) and ErbB2 are approved cancer therapeutics.
  • ErbB4 is a member of the EGFR/ErbB receptor tyrosine kinase family, implicated in various cancers.
  • Research into ErbB4-targeted therapies is less advanced compared to EGFR and ErbB2.

Purpose of the Study:

  • To review the biological activities of ErbB4.
  • To explore the potential of antibodies targeting ErbB4 as cancer therapeutics.
  • To survey the role of ErbB4 antibodies in prognostic and predictive applications.

Main Methods:

  • Literature review of ErbB4 biology and antibody-targeting strategies.
  • Analysis of existing data on ErbB4 function in cancer.
  • Speculation on clinical relevance based on biological activities.

Main Results:

  • ErbB4 possesses diverse biological functions relevant to cancer.
  • Antibodies targeting ErbB4 represent a potential therapeutic strategy.
  • ErbB4 antibodies may have utility in cancer patient stratification.

Conclusions:

  • ErbB4-targeted antibodies warrant further investigation for cancer treatment.
  • The therapeutic and prognostic potential of ErbB4 antibodies needs clinical validation.
  • Understanding ErbB4's role is crucial for developing novel cancer therapies.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...